CoChat

A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial

Open access

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; none of the 16 sources its claims cite is checked for support yet.

Abstract

BACKGROUND: Some probiotics have shown efficacy for patients with irritable bowel syndrome (IBS). Lactobacillus (L.) plantarum MF1298 was found to have the best in vitro probiotic properties of 22 strains of lactobacilli. The aim of this study was to investigate the symptomatic effect of L. plantarum MF1298 in subjects with IBS. Primary outcome was treatment preference and secondary outcomes were number of weeks with satisfactory relief of symptoms and IBS sum score. METHODS: The design was a randomised double blind placebo-controlled crossover trial. 16 subjects with IBS underwent two three-week periods of daily intake of one capsule of 10(10) CFU L. plantarum MF 1298 or placebo separated by a four-week washout period. RESULTS: Thirteen participants (81%; 95% CI 57% to 93%; P = 0.012) preferred placebo to L. plantarum MF1298 treatment. The mean (SD) number of weeks with satisfactory relief of symptoms in the periods with L. plantarum MF1298 and placebo were 0.50 (0.89) and 1.44 (1.26), respectively (P = 0.006). IBS sum score was 6.44 (1.81) in the period with L. plantarum MF1298 treatment compared with 5.35 (1.77) in the period with placebo (P = 0.010). With a clinically significant difference in the IBS sum score of 2 in disfavour of active treatment, the number needed to harm was 3.7, 95% CI 2.3 to 10.9. CONCLUSIONS: This trial shows for the first time an unfavourable effect on symptoms in subjects with IBS after intake of a potential probiotic.

Overview

CoChat Summary

TL;DR

In a randomised double-blind placebo-controlled crossover trial, subjects with IBS reported worse symptoms during intake of the candidate probiotic *Lactobacillus plantarum* MF1298 than during placebo. The authors conclude this is the first trial showing an unfavourable symptomatic effect of a potential probiotic in IBS.

Key findings

  • Thirteen of 16 participants (81%; 95% CI 57% to 93%; P = 0.012) preferred placebo to *L. plantarum* MF1298.
  • Mean (SD) weeks with satisfactory relief of symptoms were 0.50 (0.89) with *L. plantarum* MF1298 versus 1.44 (1.26) with placebo (P = 0.006).
  • IBS sum score was 6.44 (1.81) with *L. plantarum* MF1298 versus 5.35 (1.77) with placebo (P = 0.010); the difference was 1.09 (1.47), and the number needed to harm was 3.7 (95% CI 2.3 to 10.9) for a clinically significant ≥2-point difference in disfavour of active treatment.
  • Diarrhoea score was also higher with active treatment: 6.36 (1.99) versus 5.50 (1.71) with placebo (P = 0.004).

Methods

  • Randomised, double-blind, placebo-controlled crossover trial with a one-week run-in, two three-week treatment periods, and a four-week washout; 16 subjects with IBS according to Rome II criteria were analysed after daily intake of one capsule of 10^10 CFU *L. plantarum* MF1298 or placebo.
  • Primary outcome was treatment preference; secondary outcomes were number of weeks with satisfactory relief of symptoms and IBS sum score; faecal *L. plantarum* was assessed by real-time PCR, and adverse events were noted.
  • Analysis used modified intention-to-treat; paired and independent t tests, Wilson method for preference CI/P value, marginal homogeneity test for satisfactory relief, and Walter’s method for number needed to harm.

Limitations

  • The paper states that heterogeneity in bowel-habit predominance meant it could not identify aggravation of a specific symptom, that a type I error cannot be excluded, and that the IBS sum score was not validated for responsiveness or clinically significant differences; the chosen 2-point difference may be high given the run-in mean of 5.97.
  • The authors also note older age and a somewhat different IBS subgroup distribution than in corresponding studies, raising questions about external validity, and state that a longer intervention would have strengthened internal validity but increased drop-out.
  • Evident from the text: the analysed sample was small (16 participants), treatment periods were short (three weeks each), and endotoxins in the preparations were not checked.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/1471-230x-10-16

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1 Flow chart of the participants through the trial.
Figure 1 Flow chart of the participants through the trial.CC BY · PubMed Central
Figure 2 IBS sum score during the trial by allocation group. The results are given as mean with SEM.
Figure 2 IBS sum score during the trial by allocation group. The results are given as mean with SEM.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 12 Not checked · 34 Own results and interpretations

10 more claims

Create a free account to see all 46 claims and to verify the 16 references still open.

See all claims — free account
  • It may state two separate claims as one. 18
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 25 references

Research works printed but not linked: 1

  1. FAO/WHO Expert Consultation Group: Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001, Argentina: FAO/WHO

Cited by

See all 103

Metadata

Authors
Ligaarden, S. C., Axelsson, L., Naterstad, K., Lydersen, S., & Farup, P. G.
Affiliations
  • Innlandet Hospital Trust (NO)
  • Nofima (NO)
  • Norwegian University of Science and Technology (NO)
Corresponding author
Ligaarden, Solveig C
Venue
BMC Gastroenterology
Published
2010-02-10
Volume
10
Issue
1
Pages
16-16
ISSN
1471-230X (ISSN-L)
OpenAlex
W2037366651
Cited by
103
References
26
Citations by year
2026: 4 · 2025: 2 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 13 · 2013: 6 · 2012: 14
FWCI
10.20
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • BMC Gastroenterology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
irritable bowel syndrome, probiotics, treatment preferences, symptom relief, number needed to harm, placebo comparison
MeSH terms
Adult, Aged, Constipation, Diarrhea, Feces, Female, Humans, Male, Middle Aged, Species Specificity, Abdominal Pain, Patient Satisfaction, Probiotics, Irritable Bowel Syndrome, Lactiplantibacillus plantarum

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. https://app.cochat.ai/papers/10.1186/1471-230x-10-16
The paper
Ligaarden, S. C., Axelsson, L., Naterstad, K., Lydersen, S., & Farup, P. G. (2010). A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterology. https://doi.org/10.1186/1471-230x-10-16

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.